1. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan
- Author
-
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A. Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, and Tetsuju Sekiryu
- Subjects
Faricimab ,Neovascular age-related macular degeneration ,Treat-and-extend regimen ,Visual acuity ,Retinal morphology ,Choroidal thickness ,Medicine ,Science - Abstract
Abstract This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter. If wet macula persisted at the third month, a fourth dose was administered, followed by the TAE regimen. After 1 year, improvements in visual acuity (0.44 ± 0.46 [baseline] to 0.34 ± 0.48; p
- Published
- 2024
- Full Text
- View/download PDF